Capricor Initiates Rolling Submission of Biologics License Application (BLA) for Deramiocel (CAP-1002)
Capricor Therapeutics Initiates Rolling Submission of Biologics License Application (BLA) for Deramiocel (CAP-1002) for the Treatment of Duchenne Cardiomyopathy Capricor Therapeutics announced it has begun the rolling submission of its Biologics License Application (BLA) with…Learn More
